Placeholder Image

Subtitles section Play video

  • The following content is provided under a Creative

  • Commons license.

  • Your support will help MIT OpenCourseWare

  • continue to offer high quality educational resources for free.

  • To make a donation or view additional materials

  • from hundreds of MIT courses, visit MIT OpenCourseWare

  • at ocw.mit.edu.

  • JOANNE STUBBE: What I want to do today

  • is finish up module 7 on reactive oxygen species

  • and then move on into the last module, which we are obviously

  • not going to get completely through.

  • We're going to be focused mostly on purines

  • and maybe some pyrimidines.

  • And I'll give you a big overview of what

  • I think the things are you need to think

  • about in nucleotide and deoxynucleotide metabolism

  • as a starting point.

  • OK.

  • So we've been talking about module 7 and, in this section,

  • how you control reactive oxygen species for signaling.

  • We were going through the generic overview.

  • And at the end of the last lecture,

  • this is the system we were talking

  • about using epidermal growth factor

  • receptor, which we've now looked at quite a bit as an example.

  • But what I wanted to point out is

  • that it's not limited to epidermal growth factor

  • receptor.

  • So you have insulin growth factor receptor,

  • nerve growth factor signaling, VEGF, IL-1, IL-4, et cetera.

  • And all of these things are all distinct.

  • They all have different signaling cascades.

  • But the generic approach that we've

  • been looking at in the Kate Carroll paper is also,

  • I think, applicable to these other systems.

  • And so what I wanted to do was just

  • make one more point with this, and then what I'm going to do

  • is summarize the general principles

  • of post-translational modification

  • by anything-- we're using post-translational modification

  • by sulfenylation and then briefly come back

  • to the methods used.

  • But we spent a lot of time in recitations in 11 and 12

  • focused on methods, so I'm not going

  • to spend very much time on that.

  • It's also in your PowerPoint handouts.

  • So the key thing here is the general--

  • is we have EGF, OK, so that's Epidermal Growth Factor

  • in the membrane.

  • We have epidermal growth factor receptor, which you all

  • know has to dimerize and you all know, at this stage,

  • is a tyrosine kinase.

  • And the key thing we're going to be focused on

  • is if we modify these proteins, what is

  • the biological consequence, OK?

  • Do you have any biological consequence?

  • And if you don't, it's probably just an artifact of the fact

  • that cysteines react rapidly with hydrogen-- not rapidly,

  • but they react with hydrogen peroxide

  • at some level to give you modification.

  • So this is all, I'm just going to say,

  • tyrosine kinase activity.

  • We've already gone through that.

  • And what happens is you activate the NOX proteins.

  • And in this case, it's the NOX2 isozymes.

  • And this is outside, and this is inside the cell.

  • And NOX2 can generate superoxide--

  • OK, so let's just put this in parentheses--

  • which can rapidly generate hydrogen peroxide.

  • And so the issue is that the superoxide and all

  • of the hydrogen peroxide needs to come

  • from the outside of the cell to the inside of the cell.

  • OK.

  • So we have hydrogen peroxide.

  • And what is hydrogen peroxide doing?

  • So the model is--

  • and this is what we've been focusing on--

  • that the hydrogen peroxide can modify the cysteine

  • by sulfenylation, OK?

  • So we can go from SH to SOH.

  • And in the case of the tyrosine kinase

  • and in the paper you had to read,

  • it turns out that tyrosine kinase by activity assays

  • was more active.

  • So it's phosphorylated.

  • It's sulfenylated.

  • That leads to higher activity.

  • That means it's potentially biologically interesting.

  • And we also, in the Kate Carroll paper,

  • looked not only at the activity, but we looked downstream

  • at the signaling pathways, and we

  • saw signaling as defined by phosphorylation events.

  • We saw more signaling.

  • So those are the kinds of peak criteria

  • people are looking at for being biologically interesting.

  • Now, what we also have is a key control,

  • and, in these cascades, like over there, we also have PTP.

  • And that's Protein Tyrosine Phosphatase.

  • And these proteins all have a cysteine at the active site.

  • We talked about this before.

  • And the cysteine at the active site, what can it do?

  • It can really sort of dephosphorylate

  • the tyrosine kinase.

  • And if you remove the phosphate, the activity is lowered.

  • OK.

  • So again, you have something that activates,

  • something that removes it.

  • But what we also know-- so this is the active form,

  • and this is the key in all these signaling events.

  • And so what we also have-- so let me

  • go over here, since I didn't leave quite enough room.

  • So we have PTP that can also react with hydrogen peroxide

  • to become sulfenylated.

  • That's the inactive form.

  • So when it's in this state, basically, you put a roadblock

  • in this pathway.

  • So this is inactive.

  • OK.

  • And the Carroll paper spent a lot of time trying to define--

  • there are lots of protein tyrosine phosphatases

  • inside the cell-- not anywhere near as many as kinases.

  • So one protein tyrosine phosphatase

  • services many proteins.

  • But both of these guys are regulated by sulfenylation.

  • And there's one third thing, and so this is just

  • giving us the big picture now.

  • If you have hydrogen peroxide in the cell,

  • I've already told you that there are enzymes that

  • can degrade hydrogen peroxide--

  • peroxiredoxins.

  • And so that removes the hydrogen peroxide,

  • which then prevents these things from happening.

  • So you have peroxiredoxins, which I already talked about.

  • And so the hydrogen peroxide concentration goes down.

  • So that's another mechanism of control.

  • OK.

  • So the take-home message is shown in this slide.

  • It's shown in the papers you had to read.

  • And there are many proteins that have

  • some variation on this theme, and this

  • is a really active area of research

  • to look at this in more detail.

  • OK.

  • Yeah?

  • AUDIENCE: The tyrosine kinase activity, [INAUDIBLE] 160%

  • or something.

  • I was just wondering how they actually

  • classified that as [INAUDIBLE].

  • JOANNE STUBBE: Active?

  • So, I mean, in biology, that's a huge effect.

  • AUDIENCE: OK.

  • JOANNE STUBBE: So, I mean, to somebody

  • that's doing something in the test tube, a factor of two

  • is nothing.

  • In biology, that's all it takes.

  • So the question is, is it enough?

  • And you should always ask that question.

  • And then you've got to look at the consequences,

  • and you do more experiments.

  • If you hadn't seen any effect, well, maybe you

  • didn't have the right proteins in there,

  • and you need five more proteins to assay, which

  • would give you a bigger effect.

  • OK.

  • So that's the issue with all of these problems.

  • That particular experiment, if you go back and look at it,

  • was done in crude extracts, OK.

  • And the activity is extremely low.

  • They had to use a luciferase assay

  • to be able to measure this and amplify the signal, OK,

  • which probably has a lot of issues with--

  • can have a lot of issues.

  • So if you're not happy with that,

  • then you're going to have trouble in biology.